This document lists various psychiatric medications grouped by class and their major safety concerns. The classes included are MAOIs, tricyclic antidepressants, SSRIs, SNRIs, atypical and typical antipsychotics, anticonvulsants, benzodiazepines, and other classes. The major safety concerns across these classes include risks of hypertensive crisis, cardiovascular effects, serotonin syndrome, seizures, addiction, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, metabolic effects, and liver toxicity.
This document lists various psychiatric medications grouped by class and their major safety concerns. The classes included are MAOIs, tricyclic antidepressants, SSRIs, SNRIs, atypical and typical antipsychotics, anticonvulsants, benzodiazepines, and other classes. The major safety concerns across these classes include risks of hypertensive crisis, cardiovascular effects, serotonin syndrome, seizures, addiction, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, metabolic effects, and liver toxicity.
This document lists various psychiatric medications grouped by class and their major safety concerns. The classes included are MAOIs, tricyclic antidepressants, SSRIs, SNRIs, atypical and typical antipsychotics, anticonvulsants, benzodiazepines, and other classes. The major safety concerns across these classes include risks of hypertensive crisis, cardiovascular effects, serotonin syndrome, seizures, addiction, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, metabolic effects, and liver toxicity.
This document lists various psychiatric medications grouped by class and their major safety concerns. The classes included are MAOIs, tricyclic antidepressants, SSRIs, SNRIs, atypical and typical antipsychotics, anticonvulsants, benzodiazepines, and other classes. The major safety concerns across these classes include risks of hypertensive crisis, cardiovascular effects, serotonin syndrome, seizures, addiction, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, metabolic effects, and liver toxicity.